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Introduction. Ampullary cancers represent a subset of periampullary cancers, comprising only 0.2% all gastrointestinal cancers.
Localized disease is primarily managed by a surgical intervention, called pancreaticoduodenectomy (PD), followed in many
cases by the administration of adjuvant chemotherapy (CT) or chemoradiation therapy (CRT). However, there are no clear
evidence-based guidelines to aid in selecting both the modality and regimen of adjuvant therapy for resected Ampullary
carcinoma. Methods. We retrospectively analyzed 54 patients at KU Cancer Center, who had undergone endoscopic resection or
pancreaticoduodenectomy (PD) for Ampullary cancer from June 2006 to July 2016. We obtained patients’ baseline characteristics,
clinical presentation, pathology, treatment modality, recurrence pattern, and survival outcomes. The time-to-events data were
compared using Kaplan-Meier methods. A univariate and multivariate Cox proportional hazards regression was performed to
evaluate factors associated with overall survival (OS) and generate hazard ratios (HR). Results. The mean age of the 54 patients
was 68 (37-90). 38 (70%) were males and 16 (30%) were females. Most of the patients were Caucasian (76%). Approximately
half of all patients had a history of smoking, 20% had alcohol abuse, and 13% had pancreatitis. Among the 54 patients
with localized cancers, 9 (16%) were treated definitively with nonoperative therapies, usually due to a prohibitive comorbidity
profile, performance status, or unresectable tumor. 45 out of 54 patients (83%) underwent surgery. Of the 45 patients who
underwent surgery, 18 patients (40% of the study cohort) received adjuvant therapy due to concerns for advanced disease as
determined by the treating physician. 13 patients (24%) received adjuvant CT and 5 patients (9.2%) received CRT. The remaining
27 patients (50%) underwent surgery alone. The median OS for the entire study cohort was 30 months. When compared to
surgery alone, adjuvant therapy with either CT or CRT had no statistically significant difference in terms of progression-free
survival (p=0.56) or overall survival (p=0.80). In univariate Cox proportional hazards regression analysis, high-risk features
like peripancreatic extension (16%) and perineural invasion (26%) were found to be associated with poor OS. Lymph node
metastasis (29%) did not significantly affect OS (HR 1.42, 95% CI [0.73-1.86]; p=0.84). Lymphovascular invasion (29%) was not
associated with poor OS (HR 1.22, 95% CI [0.52, 2.96]; p=0.76). In multivariate Cox regression analysis, only age group>70
years was significantly associated with OS , while other factors, including the receipt of adjuvant therapy, lymph nodes, positive
margin, and lymphovascular, perineural, and peripancreatic involvement, were not significantly associated with OS. These
results are likely due to small sample size. Conclusions. Despite numerous advances in both cancer care and research, efforts
in rare malignancies such as Ampullary cancer remain very challenging with a clear lack of an evidence-based standard of
care treatment paradigm. Although adding adjuvant therapies such as chemotherapy or chemoradiotherapy is likely to improve
survival in high-risk disease, there is no standardized regimen for the treatment of Ampullary cancer. More research is required to
elucidate whether statistically and clinically relevant differences exist that may warrant a change in the current adjuvant treatment
strategies.
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1. Introduction
Ampullary carcinoma is a rare malignant tumor originating
from the Ampulla of Vater [1, 2] The reported incidence is
less than one per 100,000 in an autopsy series and in the
general population comprises of 0.2% of all gastrointestinal
tumors [1]. In 90% of patient cases, this represents a primary
presentation with a predominance of Caucasian males being
affected over other races and gender [3]. In patients with
hereditary polyposis syndromes, the incidence of Ampullary
cancer is multifold and presents at an earlier age warranting
surveillance endoscopy [4].
Previous retrospective studies have assessed the dif-
ference in prognosis of Ampullary carcinomas based on
immunohistologic subtypes. Pancreaticobiliary subtype ver-
sus intestinal subtype showed a significant difference of
almost 10-fold in median survival, 16 vs. 116 months, respec-
tively [5]. In addition to immunohistochemical subtypes,
nodal status was also found to have an impact on survival.
Patients with node-negative, nonpancreatobiliary type had
an excellent prognosis with 5-year survival rate of 88%,
while those with node-positive, pancreatobiliary type had
a poor prognosis with a 5-year survival of 20%. Patients
with node-positive, nonpancreaticobiliary or node-negative,
pancreatobiliary type had an intermediate prognosis with
a 5-year survival of 47%. A recent meta-analysis reported
that pancreatobiliary type predicted a worse overall survival
(hazard ratio [HR] 1.84, 95% CI 1.49- 2.27; p< 0.001) and
disease-free survival (HR 1.93, 95% CI 1.23-3.01; p=0.004)
[6]. On the other hand, other studies failed to replicate
similar findings, limiting their utility in diagnostic algo-
rithms. Emerging evidence suggests an increased complexity
of tumor subtypes such as the existence of a mixed subtypes
which warrants further research instead of making treatment
decisions based on immunohistologic subtypes alone [7].
Patients with localized disease are primarily managed
by pancreaticoduodenectomy (PD), often followed by the
administration of adjuvant chemotherapy (CT) or chemora-
diation therapy (CRT) [2]. However, given the paucity of
clinical evidence, current treatment recommendations in the
adjuvant setting are not included in published consensus like
NCCN or ESMO guidelines [8]. Retrospective and prospec-
tive studies have investigated the role of adjuvant therapy
in this context; however, the evidence remains inconclusive.
Our retrospective, single-center study was conducted to
evaluate whether any survival advantages exist with either
adjuvant chemotherapy or chemoradiotherapy compared to
surgery alone in the management of resected Ampullary
carcinoma.
2. Methods
This was a retrospective study conducted at the Kansas
University Cancer Center. Data was collected on patients
with a diagnosis of Ampullary adenocarcinoma who were
treated at our institution between 2006 and 2016. Our study
enrollment was over a period of 10 years from 2006 to 2016
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Figure 1: Overall survival (OS) of study cohort.
with a followup of at least 2 years for each patient in order to
obtain data relevant for long-term survival analysis.
The Institutional Review Board approved this retro-
spective study. Data collection on eligible patients included
patient baseline characteristics, clinical presentation, pathol-
ogy, treatment modality, recurrence, and survival. Statistical
analysis was performed using SPSS 22.0 with statistical
significance established at p<0.05. Both the Kaplan-Meier
method and log-rank were used to compare the time-to
events. Univariate andmultivariate Cox proportional hazards
regression model were created to identify factors associated
with OS. Of note, many of the older cases included in the
study had no immunostaining performed by pathologists.
Hence, we were unable to evaluate prognostic association
with immunohistologic subtypes.
3. Results
A total of 54 patients with Ampullary adenocarcinoma
were selected for evaluation. The epidemiology, clinical
presentation, pathologic features, and staging of Ampullary
carcinoma at baseline are presented in Table 1. The mean
age of our patient cohort was 68 years. There were more
males patients than females, 38 vs. 16 respectively. Most of
our patients were Caucasians (76%). Approximately half of
the patients (52%) had a history of smoking, 20%were alcohol
abusers, and 13% had a history of pancreatitis.
Nine patients were treated nonoperatively, secondary to
a prohibitive comorbidity profile, performance status, or
an unresectable tumor. Adjuvant treatment was adminis-
tered after surgery because of concerns for advanced dis-
ease determined by the treating physician in 18 patients:
13 (24%) received chemotherapy and 5 (9.2%) received
chemoradiation therapy. The remaining 27 (50%) patients
underwent surgery alone. The median OS for the study
cohort was found to be 30months (Figure 1). Recurrence was
noted in 40% of patients who underwent surgery. Patients
treated with adjuvant therapies following PD had a more
locally advanced disease than those who had surgery alone.
Most patients who received adjuvant therapy after surgical
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Table 1: Baseline Characteristics.
Variable
Results
(n=54)
Mean
(%)
Age (years)
n 54
Mean 68
STD 11.2
Gender
Female 16(30%)
Male 38(70%)
Race
Caucasian 41 (76%)
African American 3 (5%)
Other 10(19%)
Comorbidities
Smoking 28(52%)
Alcohol Use 11(20%)
History of Pancreatitis 7(13%)
Diabetes 19(35%)
Tumor Characteristics
ECOG Score 0-1 15(28%)
Elevated CA-19 (>34) 19(36%)
Biliary Stenting (pre-OP) 39(74%)
Tumor Histology 28(44%)
Ductal Adenocarcinoma 38(72%)
Adenocarcinoma not otherwise specified 8(15%)
Mucinous Adenocarcinoma 4(9%)
Tumor Grade
G1: Well Differentiated 5(9%)
G3: Moderately Differentiated 33(61%)
Unknown 16(29%)
Tumor stages(TNM)
Stage I 13(24%)
Stage II 9(20%)
Stage III 25(44%)
Stage IV 7(12%)
resection had positive prognostic features (50% had positive
LN and 40% had T4 disease). When compared to surgery
alone, adjuvant chemotherapy or chemoradiation therapy
failed to demonstrate a statistically significant difference in
terms of progression-free survival (PFS) (p=0.56) or OS
(p=0.80) (Figure 2). When patients with TNM stage I or II
disease were compared to patients with TNM stage III or
IV disease, a median survival difference was noted; however,
this difference was not at the statistical significance level
(p=0.7) due to the small number of patients in stage I and
II cohort (Figure 3).The 5-year survival rates of patients who
underwent surgery alone in our cohort were 53%, which is
within the 30-60%historical range published in the literature.
Table 2: Univariate Analyses.
Characteristics Hazard Ratio (95% CI) P-value
Age 1.22 (0.52-2.96) 0.6291
Gender (Female vs. Male) 1.06 (0.70-1.06) 0.8504
Smoking (Yes vs. No) 1.24 (0.48-1.78) 0.7920
Diabetes (Yes vs. No) 0.91 (0.42-1.02) 0.5930
Lymphovascular 1.22 (0.52-2.96) 0.769
invasion (Yes vs. No)
Lymph node status
(+ve vs. -ve)
1.42 (0.73-1.86) 0.843
Perinodal invasion 0.67 (0.49-3.21) 0.709
(Yes vs. No)
Peripancreatic 1.78 (1.42-2.65) 0.0459
extension (Yes vs. No)
Perineural
extension (Yes vs. No) 1.62 (1.33-3.02) 0.0352
Table 3: Multivariate Cox proportional hazards regression for
overall survival.
characteristics Hazard Ratio (95% CI) p- Value
Age
60-70 1.56 (0.49–4.9) 0.45
>70 3.18 (1.0–10.13) 0.04
Albumin ( >3.5 vs. < 3.5) 1.19 (0.66–2.13) 0.56
Margin(+ve vs. -ve) 1.06 (0.26-4.63) 0.193
Lvi (yes vs. no) 1.68 (0.55–5.12) 0.36
Ln (+ vs. -) 1.78 (0.35- 1.32) 0.1382
Pni (yes vs. no) 1.83 (0.62–5.38) 0.6276
Peripancreatic (Y vs. No) 4.55 (1.94, 10.64) 0.783
P-stage (>2 vs. <=2) 1.46 (0.46–4.77) 0.53
AdjuvantTherapy 1.14 (0.56–2.31) 0.72
OnUnivariate Cox proportional hazards regression, peri-
pancreatic extension (16%) and perineural invasion (26%)
were found to be associated with poor OS (Table 2). Lymph
nodemetastases were present in 29% of the cohort but did not
significantly affect OS (HR 1.42, 95% CI [0.73- 1.86]; p=0.84).
Lymphovascular invasion was present in 29% but did not
affect OS (HR 1.22, 95% CI [0.52, 2.96]; p=0.76).
In the multivariate Cox regression analysis, only age
group >70 years was significantly associated with OS. The
other general and local prognostic factors including the
receipt of adjuvant therapy (chemotherapy/radiation), lymph
nodes, positive margin status, and lymphovascular, per-
ineural, and peripancreatic extension were not significantly
associated with OS (Table 3). These results were largely
attributed to the small sample size.
4. Discussion
Ampullary cancer has a better prognosis when compared
to pancreatic cancer or cholangiocarcinoma, largely in part
due to the location of the tumor which is associated with
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Surgery plus Adjuvant Therapy 
Surgery Alone
Group
Surgery + 
Adjuvant 
treatment
(n=18)
Median
Survival
1 year 3 year 5 year 10year
32 100.0% 42.4% 22.7% 0.0%
Surgery alone (n=27) 61 92.5% 63.3% 52.9% 0.0%
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Figure 2: Survival following surgery plus adjuvant therapy vs. surgery alone.
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Figure 3: OS probability according to TNM staging.
an early onset of biliary obstruction-associated jaundice and
thus early disease detection [2, 9]. Since half of all Ampullary
carcinomas are anticipated to recur following the initial
intervention, it is of paramount importance that features
associated with recurrence risk are identified and managed
accordingly [10]. This risk is highlighted by the fact that up
to 28% of patients with T1 disease have been reported having
lymph node metastases [11]. This is the primary reason why
PD is preferred over local Ampullectomy as determining
benign vs. malignant tumor status is not routinely feasible
using only preoperative symptoms or lesion size as predictors.
Due to their earlier presentation, resection remains the only
curative treatment for patients with Ampullary cancer and is
feasible in approximately 50% compared to that of less than
10% in pancreatic adenocarcinoma. The mismatch between
tumor size and biliary obstruction explains why, compared
to pancreatic cancers, resectability of Ampullary cancer at
presentation is significantly higher. As a result, the prognosis
is considerably better than that for pancreatic cancer [11]
However, despite such an aggressive surgical intervention,
most patients will have a disease recurrence, hence justifying
a possible role for adjuvant therapies.
The role of postsurgical adjuvant treatment of Ampullary
cancer remains to be established, because of limited data
available in this rare disease. Preoperative neoadjuvant radi-
ation, chemotherapy, or chemoradiation is the available
options and has been studied with a survival benefit evident
in certain subset populations: patients withmultiplemorbidi-
ties who need preoperative optimization which may delay
surgery; patients with poor biologic behavior of neoplasm;
patients with the possibility of an interruption in therapy due
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to postoperative surgical complications [12]; or advanced dis-
ease with poor prognostic features. A significant proportion
of our cohort consisted of patients with advanced disease as
indicated by perineural invasion rate (26%), extension into
adjacent organs (37%), and peripancreatic soft tissue (16%).
Our study failed to demonstrate a survival benefit with
postoperative adjuvant therapy when compared to those
who had no adjuvant therapy. This is likely due to the
small number of patients available for comparison at our
institution. It is reasonable to assume that patients treated
with adjuvant therapies following PD had a more advanced
disease than those who had surgery alone. In our study,
for example, most patients who received adjuvant therapy
after surgical resection had positive prognostic features (50%
had positive LN and 40% had T4 disease). The 5-year
survival rates of patients who underwent surgery alone in
our cohort were 53%, which is within the 30-60% historical
range published in the literature albeit towards the upper
part of the range [13, 14]. This may be due to the use of a
standardized dissection at the time of PD [15]. To the best
of our knowledge, resection decisions were not based in
part upon histological subtypes. The limitations of our study
include a single institution analysis, retrospective design, and
a small sample size that prohibited analyses with adequate
power. Another possible limitation of our study is that, given
the small sample size, we did not control for chemotherapy
regimen or were able to compare the efficacy of combination
over single-agent chemotherapy, as it was previously reported
[16]
The poor OS observed in our study was likely due to
the high rate of tumor invasion and extension. High-risk
features such as lymph node metastases, lymphovascular
invasion, peripancreatic extension, and perineural invasion
have been known to impact OS [17]. Perineural invasion is a
predictive factor for lymph node metastases: odds ratio (OR)
of 3.0 [11]. Other predictive factors of lymph node metastases
include tumor size ≥1 cm (OR 2.1), poor histological grade
(OR 4.8), microscopic vessel invasion (OR 6.6), and depth
of invasion > pT1 (OR 4.3; all p< 0.05). In a recent study
by Zhao and colleagues, the degree of tumor infiltration
correlated with recurrence (p=0.014). Extraduodenal local
resection (p=0.026) was associated with increased survival
[9]. Given the significant association of survival reportedwith
peripancreatic and perineural tumor extension, which was
also found in our study, this indicates a role for adjuvant
therapy especially in high-risk disease. In accordance to
survival trends published in literature, patients with either
stage I or II Ampullary cancer demonstrated a trend toward
survival benefit over more advanced stages [9].
The role of adjuvant postoperative chemotherapy or
chemoradiation for Ampullary Adenocarcinoma has been
investigated previously in a few studies with conflicting
results. The ESPAC-3 trial randomized patients with peri-
ampullary cancers (69.4%[n=297]with Ampullary adenocar-
cinoma)whounderwent PD to either observation or adjuvant
chemotherapy. Although no significant differences were seen
in the primary analysis, adjuvant chemotherapy with fluo-
rouracil plus folinic acid or gemcitabine was associated with
improved survival after controlling for prognostic variables
[16]. However, both the multicentered EORTC-40891 trial
in patients with periampullary cancers (44%[n=92] had
Ampullary cancer) and a single-center study in India (n=104)
failed to show a survival benefit with adjuvant chemoradi-
ation (with fluorouracil) following PD [18, 19]. Both studies
were powered adequately to detect significant differences.
On the other hand, at least one recent meta-analysis
(n=3361 patients) using a pooled analysis reported a signifi-
cant survival benefit of adjuvant chemoradiation (HR=0.75,
p=0.01) following PD [20]. Furthermore, they also found
strong associations between postoperative chemoradiation
and survival in patients with positive lymph nodes and T3/T4
tumors, although they had a limited number of eligible
subjects (n=3) for this subgroup analysis [20].
Retrospective studies have supported the selective admin-
istration of adjuvant or neoadjuvant therapy to patients with
periampullary cancers with high-risk features. Bhatia et al.
found a significant survival benefit of adjuvant chemoradia-
tion for patients with lymph node positive Ampullary cancer
(23%[n=29]) [17]. Other retrospective studies including Lee
et al. (33%[n=13] received adjuvant chemoradiation) and
Narang et al. (55%[n=66] received adjuvant chemoradiation)
found a survival benefit albeit only after multivariate analysis
[13, 21]. Interestingly, most recently a retrospective analysis
of patients from the Surveillance, Epidemiology, and End
Results (SEER) database found significantly longer cancer-
specific survival and OS in patients with N2 nodal status
who underwent adjuvant radiotherapy without concomitant
chemotherapy [22].
Most relevant in comparison to our findings were results
from a similar single-center study consisting of 52 patients
who underwent potentially curative PD [23]. As in our
study, no survival benefit was observed with adjuvant ther-
apy; however, they did observe a trend towards improved
survival with chemoradiation as opposed to chemotherapy.
Perineural invasion was associated with decreased survival,
as observed in our study. Lymphovascular invasion was
associated with decreased survival, unlike our study. These
differences between study findings are likely due to the small
patient population available for analysis yet are relevant
findings for prognostication. Findings from our single-center
study along with evidence from other studies support the
rationale for more prospective investigations to establish the
role of adjuvant therapies in the postsurgical setting especially
in higher-risk patients with Ampullary adenocarcinoma.
Ampullary adenocarcinoma is a rare cancer and most
series have relatively small numbers. As a result, analysis of
factors influencing outcome has been limited. The strengths
of the current study include its comprehensive study of the
prognostic factors of such a rare cancer extracted from a
prospectively maintained database with robust clinical data.
However, several limitations should be acknowledged. First,
this analysis suffers from the limitations inherent in its
retrospective, single-institution design. Second, the surgical
resectability criteria for patients who underwent surgery and
those who did not are difficult to determine retrospectively
and therefore introduce physician/patient bias that is not
uncommon in a retrospective study. Third, the adjuvant
chemotherapy regimens used may have had variable effects;
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however, no standardized regimen in adjuvant setting exists
for Ampullary cancer. Finally, there was no stratification by
histological subtype and/or other molecular profiling due
to unavailability of archival tissue. The multivariate analysis
of prognostic features did not reach statistical significance
due to small sample size in our study. Hence, in future, a
multicenter prospective study with a larger sample size is
warranted to conduct analyses with adequate power.
5. Conclusions
Despite numerous advances in cancer care and research,
efforts in raremalignancies such as Ampullary cancer remain
very challenging with a clear lack of an evidence-based stan-
dard of care treatment paradigm. Although adding adjuvant
therapies such as CT or CRT likely improves survival in
patients with high-risk disease, no standardized regimen
exists for the treatment of Ampullary cancer. More research
is required to elucidate whether clinically relevant differences
exist that may warrant a change in existing treatment strate-
gies. Stratification by histological subtype, staging, prognostic
factors, and/or other molecular profiling in large studies may
enable personalized treatment decision making.
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